Fig. 2.
Plasma viral loads in macaques passively administered PGT126 or DEN3 mAbs before being challenged with a single dose of SHIVSF162P3. (a) Plasma viral loads for animals challenged vaginally 24 hours after being administered 10 mg/kg of PGT126 (green), 2 mg/kg of PGT126 (black), 0.4 mg/kg of PGT126 (blue) or 10 mg/kg of the isotype control DEN3 (red). All animals receiving 10 mg/kg were protected and showed no detectable viremia, three out of five became infected in the 2 mg/kg treatment group and four out of five became infected in the 0.4 mg/kg treatment group. (b) Plasma viral loads for animals challenged rectally 24 hours after being administered 10 mg/kg of PGT126 (green), 2 mg/kg of PGT126 (black), 0.4 mg/kg of PGT126 (blue) or 10 mg/kg of the isotype control DEN3 (red). One out of four animals receiving 10 mg/kg became infected, two out of four became infected in the 2 mg/kg treatment group and four out of four became infected in the 0.4 mg/kg treatment group. All animals given the isotype control antibody became viremic regardless of being vaginally or rectally challenged. Viral detection limit was 50 copies/ml and 60 copies/ml for the vaginal and rectal challenge experiments, respectively.